From Oulu to the world – Finnadvance is speeding up its growth
Finnadvance has become part of Finland’s efforts on nanobiotechnology derived therapeutics by joining a new research consortium of pharmaceutical technology and academic research organisations.
A research project, EVE – EV Ecosystem for Theranostic Platforms, has been set up to develop new types of nanobiotechnological solutions for the treatment and early diagnostics of severe progressive diseases, such as central nervous system degenerative diseases and cancer. The consortium’s research will leverage blood-derived extracellular vesicles for potential drug delivery vehicles and biomarkers. The project is founded by Business Finland and it will last for three years. Finnadvance joins forces with partners including the Finnish Red Cross Blood Service, Orion Pharma, University of Helsinki, University of Eastern Finland, Tampere University, VTT Oulu, UPM Biomedicals, the Biobank of Eastern Finland and innovative SMEs, Kaivogen, Timegate Instruments, Bionavis and Afekta.
Oulu-based Finnadvance develops microfluidic devices for in-vitro microvascular network generation that can be fitted with wither a pump-based perfusion system, or a gravity-powered perfusion system on-chip. In January, the company was invited to speak at the WT | Wearable Technologies Conference EUROPE in Munich. Finnadvance’s CEO, Prateek Singh, presented their research on microtechnologies for on- and off-body research. Finnadvance is also the winner in the last year edition of the world’s leading Innovation World Cup Series TechStartup.
R&D Manager, Finnish Red Cross Blood Service